Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Actuate Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
27 August 2026
2026 BD opportunity scan for Actuate Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
9 min read
AbelZeta Pharma, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
27 August 2026
2026 BD opportunity scan for AbelZeta Pharma, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.
Latest Hotspot
8 min read
NCT07446452 Disitamab Vedotin HER2-Low Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07446452 clinical trial report covering Disitamab Vedotin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07444892 Levodopa hydrate Diabetic Retinopathy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07444892 clinical trial report covering Levodopa hydrate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07446933 Vasopressin Cesarean Scar Pregnancy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07446933 clinical trial report covering Vasopressin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07447570 Iparomlimab/Tuvonralimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07447570 clinical trial report covering Iparomlimab/Tuvonralimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07447050 Riluzole Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07447050 clinical trial report covering Riluzole, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07445815 Recombinant human anti-rabies virus monoclonal antibody (Lanzhou Institute of Bi Rabies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07445815 clinical trial report covering Recombinant human anti-rabies virus monoclonal antibody (Lanzhou Institute of Bi, Phase 2, endpoints, sponsor, g
Latest Hotspot
8 min read
NCT07444437 LM-103 Resectable Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07444437 clinical trial report covering LM-103, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07444684 SHR-1139 Pyoderma Gangrenosum Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07444684 clinical trial report covering SHR-1139, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07444918 Temozolomide Relapsed Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07444918 clinical trial report covering Temozolomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07446270 Tunlametinib Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07446270 clinical trial report covering Tunlametinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.